FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025797605> ?p ?o ?g. }

• W2025797605 abstract "Abstract Background Recent in vivo and in vitro studies in non-neuronal and neuronal tissues have shown that different pathways of macrophage activation result in cells with different properties. Interleukin (IL)-6 triggers the classically activated inflammatory macrophages (M1 phenotype), whereas the alternatively activated macrophages (M2 phenotype) are anti-inflammatory. The objective of this study was to clarify the effects of a temporal blockade of IL-6/IL-6 receptor (IL-6R) engagement, using an anti-mouse IL-6R monoclonal antibody (MR16-1), on macrophage activation and the inflammatory response in the acute phase after spinal cord injury (SCI) in mice. Methods MR16-1 antibodies versus isotype control antibodies or saline alone were administered immediately after thoracic SCI in mice. SC tissue repair was compared between the two groups by Luxol fast blue (LFB) staining for myelination and immunoreactivity for the neuronal markers growth-associated protein (GAP)-43 and neurofilament heavy 200 kDa (NF-H) and for locomotor function. The expression of T helper (Th)1 cytokines (interferon (IFN)-γ and tumor necrosis factor-α) and Th2 cytokines (IL-4, IL-13) was determined by immunoblot analysis. The presence of M1 (inducible nitric oxide synthase (iNOS)-positive, CD16/32-positive) and M2 (arginase 1-positive, CD206-positive) macrophages was determined by immunohistology. Using flow cytometry, we also quantified IFN-γ and IL-4 levels in neutrophils, microglia, and macrophages, and Mac-2 (macrophage antigen-2) and Mac-3 in M2 macrophages and microglia. Results LFB-positive spared myelin was increased in the MR16-1-treated group compared with the controls, and this increase correlated with enhanced positivity for GAP-43 or NF-H, and improved locomotor Basso Mouse Scale scores. Immunoblot analysis of the MR16-1-treated samples identified downregulation of Th1 and upregulation of Th2 cytokines. Whereas iNOS-positive, CD16/32-positive M1 macrophages were the predominant phenotype in the injured SC of non-treated control mice, MR16-1 treatment promoted arginase 1-positive, CD206-positive M2 macrophages, with preferential localization of these cells at the injury site. MR16-1 treatment suppressed the number of IFN-γ-positive neutrophils, and increased the number of microglia present and their positivity for IL-4. Among the arginase 1-positive M2 macrophages, MR16-1 treatment increased positivity for Mac-2 and Mac-3, suggestive of increased phagocytic behavior. Conclusion The results suggest that temporal blockade of IL-6 signaling after SCI abrogates damaging inflammatory activity and promotes functional recovery by promoting the formation of alternatively activated M2 macrophages." @default.
• W2025797605 created "2016-06-24" @default.
• W2025797605 creator A5003728942 @default.
• W2025797605 creator A5004393979 @default.
• W2025797605 creator A5009696633 @default.
• W2025797605 creator A5035359720 @default.
• W2025797605 creator A5043083974 @default.
• W2025797605 creator A5046708618 @default.
• W2025797605 creator A5065204759 @default.
• W2025797605 date "2012-02-27" @default.
• W2025797605 modified "2023-10-14" @default.
• W2025797605 title "Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice" @default.
• W2025797605 cites W1569061064 @default.
• W2025797605 cites W1592314518 @default.
• W2025797605 cites W1595606162 @default.
• W2025797605 cites W1602943807 @default.
• W2025797605 cites W1653545152 @default.
• W2025797605 cites W1970024238 @default.
• W2025797605 cites W1978172024 @default.
• W2025797605 cites W1983325630 @default.
• W2025797605 cites W1986913334 @default.
• W2025797605 cites W1987874420 @default.
• W2025797605 cites W1991634993 @default.
• W2025797605 cites W1996384328 @default.
• W2025797605 cites W1996517410 @default.
• W2025797605 cites W1997507612 @default.
• W2025797605 cites W2000846863 @default.
• W2025797605 cites W2001717792 @default.
• W2025797605 cites W2002482328 @default.
• W2025797605 cites W2003805774 @default.
• W2025797605 cites W2006517495 @default.
• W2025797605 cites W2006708761 @default.
• W2025797605 cites W2007229760 @default.
• W2025797605 cites W2009109694 @default.
• W2025797605 cites W2011411078 @default.
• W2025797605 cites W2013683961 @default.
• W2025797605 cites W2014770545 @default.
• W2025797605 cites W2019479110 @default.
• W2025797605 cites W2023542419 @default.
• W2025797605 cites W2024814419 @default.
• W2025797605 cites W2025370895 @default.
• W2025797605 cites W2027509917 @default.
• W2025797605 cites W2032989272 @default.
• W2025797605 cites W2038689279 @default.
• W2025797605 cites W2039334993 @default.
• W2025797605 cites W2053891616 @default.
• W2025797605 cites W2054472394 @default.
• W2025797605 cites W2057378071 @default.
• W2025797605 cites W2057831959 @default.
• W2025797605 cites W2059028717 @default.
• W2025797605 cites W2063255299 @default.
• W2025797605 cites W2066385294 @default.
• W2025797605 cites W2070665570 @default.
• W2025797605 cites W2081467080 @default.
• W2025797605 cites W2081476175 @default.
• W2025797605 cites W2083946660 @default.
• W2025797605 cites W2084086889 @default.
• W2025797605 cites W2087251720 @default.
• W2025797605 cites W2088471302 @default.
• W2025797605 cites W2090023607 @default.
• W2025797605 cites W2091998173 @default.
• W2025797605 cites W2092564896 @default.
• W2025797605 cites W2092881768 @default.
• W2025797605 cites W2093705034 @default.
• W2025797605 cites W2093738970 @default.
• W2025797605 cites W2112961986 @default.
• W2025797605 cites W2116077352 @default.
• W2025797605 cites W2121438383 @default.
• W2025797605 cites W2122699286 @default.
• W2025797605 cites W2125691088 @default.
• W2025797605 cites W2126755143 @default.
• W2025797605 cites W2127522048 @default.
• W2025797605 cites W2129265758 @default.
• W2025797605 cites W2130529018 @default.
• W2025797605 cites W2132382876 @default.
• W2025797605 cites W2137399557 @default.
• W2025797605 cites W2155815888 @default.
• W2025797605 cites W2161456562 @default.
• W2025797605 cites W2162892919 @default.
• W2025797605 cites W2316504637 @default.
• W2025797605 cites W4313376337 @default.
• W2025797605 doi "https://doi.org/10.1186/1742-2094-9-40" @default.
• W2025797605 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3310810" @default.
• W2025797605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22369693" @default.
• W2025797605 hasPublicationYear "2012" @default.
• W2025797605 type Work @default.
• W2025797605 sameAs 2025797605 @default.
• W2025797605 citedByCount "168" @default.
• W2025797605 countsByYear W20257976052012 @default.
• W2025797605 countsByYear W20257976052013 @default.
• W2025797605 countsByYear W20257976052014 @default.
• W2025797605 countsByYear W20257976052015 @default.
• W2025797605 countsByYear W20257976052016 @default.
• W2025797605 countsByYear W20257976052017 @default.
• W2025797605 countsByYear W20257976052018 @default.
• W2025797605 countsByYear W20257976052019 @default.
• W2025797605 countsByYear W20257976052020 @default.
• W2025797605 countsByYear W20257976052021 @default.
• W2025797605 countsByYear W20257976052022 @default.
• W2025797605 countsByYear W20257976052023 @default.

• next